Growth Metrics

Merck (MRK) Cash from Operations (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 37.14%
Dec 31, 2025 -63.47%
Sep 30, 2025 137.53%
Jun 30, 2025 31.72%
Mar 31, 2025 -27.54%
Dec 31, 2024 -62.87%
Sep 30, 2024 64.82%
Jun 30, 2024 82.43%
Mar 31, 2024 1,156.10%
Dec 31, 2023 -96.81%
Sep 30, 2023 108.34%
Jun 30, 2023 176.62%
Mar 31, 2023 -69.77%
Dec 31, 2022 -20.92%
Sep 30, 2022 30.22%
Jun 30, 2022 -9.64%
Mar 31, 2022 -6.56%
Dec 31, 2021 6.21%
Sep 30, 2021 141.06%
Jun 30, 2021 60.48%
Mar 31, 2021 -63.64%
Dec 31, 2020 115.55%
Sep 30, 2020 -17.52%
Jun 30, 2020 171.29%
Mar 31, 2020 197.06%
Dec 31, 2019 -94.37%
Sep 30, 2019 37.03%
Jun 30, 2019 130.84%
Mar 31, 2019 -62.81%
Dec 31, 2018 28.61%
Sep 30, 2018 -17.42%
Jun 30, 2018 192.81%
Mar 31, 2018 -71.26%
Dec 31, 2017 443.21%
Sep 30, 2017 -135.30%
Jun 30, 2017 1,059.79%
Mar 31, 2017 -92.13%
Dec 31, 2016 22.25%
Sep 30, 2016 85.69%
Jun 30, 2016 -26.37%
Mar 31, 2016 -48.82%
Dec 31, 2015 28.24%
Sep 30, 2015 22.77%
Jun 30, 2015 18.08%
Mar 31, 2015 320.68%
Dec 31, 2014 -123.80%
Sep 30, 2014 87.82%
Jun 30, 2014 -1.95%
Mar 31, 2014 -21.98%
Dec 31, 2013 -23.37%
Sep 30, 2013 68.91%
Jun 30, 2013 -0.13%
Mar 31, 2013 29.41%
Dec 31, 2012 -42.37%
Sep 30, 2012 7.50%
Jun 30, 2012 35.56%
Mar 31, 2012 -33.37%
Dec 31, 2011 -29.36%
Sep 30, 2011 60.48%
Jun 30, 2011 65.72%
Mar 31, 2011 -51.37%
Dec 31, 2010 36.54%
Sep 30, 2010 -22.05%
Jun 30, 2010 143.41%
Mar 31, 2010 -39.09%
Dec 31, 2009 818.52%
Sep 30, 2009 -141.67%
Jun 30, 2009 5.11%